1 National Health Committee of the People's Republic of China National Administration of Traditional Chinese Medicine

Diagnostic and therapeutic guidance for 2019 novel coronavirus disease (version 5). As of April 20, 2020, coronavirus disease 2019 (COVID-19) has affected more than 2 million people globally. In February, 2020, China's National Health Commission and National Administration of Traditional Chinese Medicine suggested the use of probiotics in patients with severe COVID-19.We reviewed the evidence for the role of probiotics in COVID-19-related illnesses ( appendix ).

2 Wong SH

Lui RNS

Sung JJY COVID-19 and the digestive system. , 3 Guan WJ

Ni ZY

Hu Y

et al. Clinical characteristics of coronavirus disease 2019 in China. , 4 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507–13. 5 Hempel S

Newberry SJ

Maher AR

et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. 6 Allen SJ

Wareham K

Wang D

et al. Lactobacilli and Bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. 7 King S

Glanville J

Sanders ME

Fitzgerald A

Varley D Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. , 8 Hao Q

Dong BR

Wu T Probiotics for preventing acute upper respiratory tract infections. 3 Guan WJ

Ni ZY

Hu Y

et al. Clinical characteristics of coronavirus disease 2019 in China. , 4 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507–13. 9 Morrow LE

Kollef MH

Casale TB Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. , 10 Zeng J

Wang CT

Zhang FS

et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. In China, 58–71% of patients with COVID-19 were given antibiotics, and diarrhoea occurred in 2–36% of patients.When antibiotics are used, reinforcement of colonic flora using probiotics has been proposed to reduce susceptibility to subsequent infections. Although a 2012 meta-analysisshowed that probiotics have modest efficacy in reducing antibiotic-associated diarrhoea, the largest randomised, placebo-controlled trial (involving 2941 participants) showed that a 21-day treatment of combined Lactobacilli and Bifidobacteria did not reduce antibiotic-associated diarrhoea.Even if probiotics are useful, they are unlikely to have a direct effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; most patients with COVID-19 present with respiratory symptoms. However, gut–lung crosstalk has been proposed in the pathogenesis of certain respiratory conditions. Two meta-analyses reported modest efficacy of probiotics in reducing the incidence and duration of respiratory tract infections of viral origin.During the COVID-19 pandemic, 2–47% of infected patients required invasive mechanical ventilation.Two randomised controlled trials showed that critically ill patients on mechanical ventilation who were given probiotics (Lactobacillus rhamnosus GG, live Bacillus subtilis, and Enterococcus faecalis) developed substantially less ventilator-associated pneumonia compared with placebo.However, the efficacy of probiotics in reduction of intensive care unit mortality and inpatient mortality is uncertain.

11 Xu K

Cai H

Shen Y

et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. 12 Feng Z

Wang Y

Qi W The small intestine, an underestimated site of SARS-CoV-2 infection: from red queen effect to probiotics. Scarce data are available on the effect of COVID-19 on intestinal microbiota. A small case series from China revealed that some patients with COVID-19 showed microbial dysbiosis with decreased Lactobacillus and Bifidobacterium.However, animal studies (as yet, not peer-reviewed) showed that Lactobacillus acidophilus and Bacillus clausii did not reduce coronavirus receptor expression in the murine small intestine compared with control and post-Salmonella infection models.Not all probiotics are likely to be the same. Lactobacilli and Bifidobacteria are only two types of non-pathogenic bacteria and we must consider whether they can really tip the balance of a diverse gut ecosystem in combating COVID-19. To date, the rationale for using probiotics in COVID-19 is derived from indirect evidence. Blind use of conventional probiotics for COVID-19 is not recommended until we have further understanding of the pathogenesis of SARS-CoV-2 and its effect on gut microbiota. It is likely that a novel and more targeted approach to modulation of gut microbiota as one of the therapeutic approaches of COVID-19 and its comorbidities will be necessary.

JWYM reports grants from Janssen, the Hong Kong College of Physicians, and the Hong Kong Society of Gastroenterology, outside the submitted work. FKLC reports grants from Olympus Hong Kong and China, Pfizer, AstraZeneca, Takeda Pharmaceuticals, Takeda (China) Holdings, and Given Imaging; and personal fees from the American Gastroenterological Association, Medical Association of Guangdong Province, Olympus Hong Kong and China, Pfizer, AstraZeneca, Takeda Pharmaceuticals, EA Pharma, Takeda (China) Holdings, Associação dos Médicos Hospitalares da Função Pública de Macau, Pfizer Upjohn Korea, Fujifilm, Ministry of Health Singapore, and Japanese Gastroenterological Endoscopy Society. He is also an advisor and commentator for evidence-based medicine for the Ministry of Health of the People's Republic of China, Pfizer, AstraZeneca, Ministry of Health Singapore, American College of Physicians Journal Club, and Nature Reviews Gastroenterology & Hepatology, outside the submitted work. SCN reports grants from Ferring and personal fees from Takeda, AbbVie, Janssen, and Tillotts, outside the submitted work.

Supplementary Material Supplementary appendix

Article Info Publication History Identification DOI: https://doi.org/10.1016/S2468-1253(20)30122-9 Copyright © 2020 Elsevier Ltd. All rights reserved. ScienceDirect Access this article on ScienceDirect